Elevated levels of homocysteinesulfinic acid in the plasma of patients with amyotrophic lateral sclerosis: a potential source of excitotoxicity?

Lee A, Arachchige BJ, Henderson R, Aylward J, McCombe PA

Disclaimer:
Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

© The Author(s). Published by S. Karger AG, Basel
Elevated levels of homocysteinesulfinic acid in the plasma of patients with amyotrophic lateral sclerosis: a potential source of excitotoxicity?

Aven Lee¹, Buddhika Jayakody Arachchige², Robert Henderson³, James Aylward⁴ & Pamela Ann McCombe¹,⁴*

¹Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4029, Australia; ²Mass Spectrometry Facility, Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4029, Australia ³Department of Neurology, Royal Brisbane & Women’s Hospital, Brisbane, QLD 4029, Australia; ⁴Wesley Medical Research, The Wesley Hospital, Auchenflower, QLD 4066, Australia

• Corresponding author Prof PA McCombe, University of Queensland, Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Herston 4029, QLD Australia, Pamela.McCombe@uq.edu.au, phone +61419703854 fax +61 33465599
• Key words: Amyotrophic lateral sclerosis, excitotoxicity, sulphur amino acids, homocysteinesulfinic acid.

WORD COUNT = 2536

Running title: SAA in ALS
ABSTRACT

Objectives: Excitotoxicity is thought to be involved in the pathogenesis of amyotrophic lateral sclerosis. One possible source of excitotoxicity is the presence of sulphur amino acids (SAAs). In the brain of subjects with amyotrophic lateral sclerosis (ALS), there are increased levels of taurine. In the metabolism of methionine to taurine, excitatory sulphur amino acids (SAAs) are formed. These could potentially contribute to excitotoxicity in ALS. The present study has examined whether plasma levels of SAAs in 38 ALS patients differ from those of 30 healthy controls.

Methods: Plasma levels of SAAs were measured by liquid chromatography mass spectrometry.

Results: There were no significant changes in plasma cysteic acid, cysteinesulfinic acid and homocysteic acid in ALS patients, compared to healthy subjects. Significant elevations in plasma homocysteinesulfinic acic (HCSA) levels (p<0.0001) were observed in the ALS patients (75.91±15.38 nM) compared to healthy controls (54.06±8.503 nM); 50% of the ALS patients had HCSA levels that were 1.5 to 2-folds higher than those of controls. Plasma levels of HCSA differed significantly (p=0.0440) between patients with bulbar onset and spinal onset (68.57±14.20 vs 79.30±14.95 nM, respectively).

Conclusion: HCSA is elevated in the blood of subjects with ALS. Since HCSA can be transported from the blood to the CNS by active transport, has neurotransmitter properties and can activate synaptic receptors including NMDAR and mGluR, it is possible that increases in HCSA could influence glutamatergic neurotransmission and potentially contribute to excitotoxicity in some ALS patients.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a severe fatal neurodegenerative disease characterized by loss of motor neurons. There is a body of evidence implicating glutamate excitotoxicity as a contributing factor in ALS [1]. Interference with glutamate toxicity is the only therapeutic strategy that has proven to be of benefit in terms of slowing disease progression in ALS patients [2]. However, the source of the chronic glutamate toxicity in ALS is unclear.

The literature also suggests that sulphur-containing amino acids (SAAs) such as cysteic acid (CA), homocysteic acid (HCA), cysteinesulfinic acid (CSA) and homocysteinesulfinic acid (HCSA) should be considered in relation to motor system related disorders. HCA and HCSA are sulphur-containing homologues of glutamate, while CSA and CA are homologues of aspartate (Fig 1) [3, 4]. The pathway for CA and CSA synthesis has been identified. It involves the catabolism of dietary methionine cycled through the transmethylation pathway involving S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) to yield homocysteine, which can either be recycled to methionine or converted to cysteine. CSA and CA are then synthesized by sequential oxidation of cysteine to its corresponding sulfinic acid (CSA) and sulfonic acid (CA) using molecular oxygen. CSA and CA are precursors of taurine, and both molecules are substrates for decarboxylation by cysteine sulfinate decarboxylase [5]. 13C-NMR spectroscopy have revealed that the formation of taurine and hypotaurine via CSA and CA is a major pathway of cysteine metabolism in the human brain [6]. However, the biosynthetic pathway for HCA and HCSA has never been clarified but homocysteine is proposed to be the precursor of their synthesis. As no enzymes has been identified that would catalyse these reactions, the identification of these molecules in CNS tissues, therefore, has been explained by spontaneous oxidation of homocysteine, firstly to HCSA and then to HCA [7](see Fig 2).

SAAs have neurotransmitter properties and can interact with synaptic receptors such as NMDARs and metabotropic glutamate receptors to either excite or destroy neurons [8, 9]. In the ALS motor cortex, increased levels of taurine, the final product of the metabolic pathway of SAAs have been reported, suggesting that SAAs (the intermediates of this pathway) could also be increased in ALS [10]. Prior studies have shown that plasma homocysteine levels are significantly increased in ALS patients when compared to age- and sex-matched controls, suggesting that production of the oxidised by-product of homocysteine, HCSA, is likely to be increased among patients [11]. Thus, it is possible that these excitotoxins might play pathogenic roles in ALS. While SAAs are known to be synthesised and released from CNS tissues [4], the literature also highlights that several phyla that comprise the majority of the intestinal microbiota (Actinobacteria, Firmicutes and Proteobacteria) are able to
produce SAAs [12]. Here we investigated whether plasma levels of SAAs in ALS patients were different from those of healthy controls.

METHODS

Recruitment: ALS patients (n=38) were recruited from the Motor Neuron Disease Clinic at the Royal Brisbane and Women's Hospital. These patients had no underlying or prior disease. Healthy controls (n=30), with no underlying disease, who were caregivers of the ALS patients were also recruited. At entry, all ALS patients had a diagnosis of clinically definite or clinically probable ALS according to the revised El Escorial criteria. By the end of the study, 31 patients had clinically definite ALS (21 patients had died of ALS and 10 were alive with clinically definite ALS). Of the remainder, five were alive with upper motor neurone predominant disease, one had died of lower motor neurone predominant disease and one was alive with flail limb phenotype. We recorded the age, site of onset and disease duration from the time of onset of symptoms to the date of blood collection. The burden of disease at the time of blood collection was measured as the ALSFRS-R. We noted whether disease was sporadic or familial and the genotype if this was known but there was no systemic genetic screening for ALS causative genes.

Plasma samples: Samples of whole blood (fasting) were collected in BD EDTA coated vacutainers and plasma was immediately separated by centrifugation at 1500xg for 10 minutes at 4°C, transferred to microcentrifuge tubes and stored at -80°C until use. Proteins were precipitated by addition of 100 µl of 80 % acetonitrile/20 % methanol to 55 µl plasma. The mixed solution was vortexed for 2 minutes and centrifuged at 17,000xg for 10 minutes. The supernatant was collected, dried down using a rotary speed-vac and the pellet resuspended in 110 µl of 0.1 % formic acid; an aliquot of 5 µl was injected into the liquid chromatography mass spectrometry (LC-MS) system for analysis.

Measurements of L-cysteic acid (CA), L-cysteine sulfenic acid (CSA) and L-homocysteinesulfenic acid (HCSA): Measurements of CA, CSA and HCSA in plasma samples of ALS patients and healthy controls were performed liquid chromatography multiple reaction monitoring mass spectrometry (LC-MS). The calibration curves were linear over the range examined for the respective molecules (CA: 3.0-1500 nM, R²>0.9991; CSA: 1.20-1250 nM, R²>0.9995; HCSA: 3.0-1500 nM, R²>0.9996). The assay was validated using quality control (QC) samples; the accuracy of the values determined from each QC samples were within 100±10% of their expected values.

CA was separated on a Shimadzu Nexera UHPLC system with XB Amide C18 column (4.6 x 150mm) from Waters. Mobile phase used for separation were buffer A (0.1% formic acid in water) and buffer B (0.1% formic acid in 100% acetonitrile). Samples (5 µl) was loaded at 0.45 mL/min and the separation was carried out at 50% B for 6 min. Column oven and auto sampler were operated at 25°C and 5°C, respectively. Samples eluting from the column were monitored in negative ion mode with MRM on a QTRAP 5500-1 mass spectrometer (AB Sciex Instruments). The following ion source conditions were used: Curtain gas flow (40), GS1
gas flow (35), GS2 gas flow (30), ion source temp (400°C), ion source voltage (-4500v) and de-clustering potential (-80v). CSA was monitored using the precursor-product ion transitions: 152.1 > 88.1 with 5.4 min retention time.

Measurement of L-Homocysteic acid (HCA): Plasma levels of HCA was measured using Abbkine Human Homocysteic Acid (HCY) ELISA kit, following precisely the manufacturer’s instruction. This kit employs a two-site sandwich ELISA to quantify HCA in biological fluids such as plasma and serum. The capture antibody is monoclonal and the detection antibody is polyclonal. The calibration curve was linear over the range examined (0.5 nmol/ml to 8.0 nmol/ml; R²>0.998). The lower limit of quantification (LLOQ) was 0.5 nmol/ml (92 pg/ml) and all measured blood levels of HCA in healthy controls and ALS patients were above the LLOQ.

Statistics: Plasma levels of SAAs in patients and controls were compared using Mann-Whitney U test. Spearman’s correlation test was used to assess the correlation between levels of Homocysteinesulfinic acid and other variables. Power calculations were performed to guide sample size decisions; our analysis determined that a sample size of 26 or more was needed to detect moderate to strong difference effects between the two groups [based on an effect size d = 0.8, α err prob = 0.05 and Power (1-β err prob) = 0.80].

RESULTS

Subjects: The demographics of our participant cohort and clinical features of patients are summarised in Table 1. The groups were well matched with no significant differences between controls and patients.

Concentrations of SAAs in ALS patient plasma: Levels of CA, CSA and HCA in ALS patient plasma were not significantly different to those of healthy control subjects (CA: 9.137±4.252 vs 9.570±2.012 nM, p=0.0550; CSA: 7.160±3.589 vs 8.355±2.703 nM, p=0.1433; HCA: 2.817±3.252 vs 2.523±2.133 nM, p=0.8999, respectively) (Fig 3A-C). Plasma HCAS levels were significantly higher (p<0.0001) in the ALS patient group compared with the healthy control group (75.91±15.38 vs 54.06±8.503 nM, respectively) (Fig 4D). We found that 50% of the patients had plasma HCAS levels that were 1.5 to 2-folds higher than that of healthy controls. Significant difference (p=0.0440) between patients with bulbar onset and spinal onset were also observed in plasma levels of HCAS (68.57±14.20 vs 79.30±14.95 nM, respectively) (Fig 4). There were no significant correlation of HCAS levels with age (r=-0.08420, p=0.6153), ALSFRS-R (r=-0.1610, p=0.3342) or with duration of disease (r=0.1665, p=0.3179).
DISCUSSION

This study compared the levels of SAAs, which are possible sources of excitotoxicity, in the blood of patients with ALS and in controls. We measured CA, CSA and HCSA with LC-MRM-MS and HCA with ELISA. The principal finding of this study was that homocysteinesulfinic acid (HCSA) is significantly elevated in the blood of many patients with ALS, compared to controls. Specifically, we showed that half of the patient cohort had plasma HCSA levels that were 1.5 to 2 folds higher than that of controls. For the other SAAs, there were no differences between ALS patients and controls.

For HCSA, we also found differences between patients with bulbar and spinal onset ALS. Generally, patients with onset in different regions, but spread to other regions, fulfill the criteria for diagnosis of ALS, and are considered to have the same disease. However, ALS patients are heterogeneous and have different clinical features and course of disease. It is possible that there are subgroups of patients with differing etiology and pathogenesis of disease. Patients with bulbar and spinal onset ALS differ in age of onset and sex-ratio [13] and in the incidence of cognitive impairment [14]. Our finding of different levels of HCSA could support the possibility that these subgroups have differing pathological processes.

The source of the elevated HCSA could be endogenous production. HCSA, a sulphur-containing homologue of glutamate, is an oxidised metabolite of homocysteine in humans. However, the precise mechanism involved in the biosynthesis of HCSA (and HCA) has never been clarified. Previous studies found no evidence of whether the two molecules are products of oxidative metabolism of homocysteine in analogy to the route of CSA and CA formation by oxidative metabolism of cysteine [15]. In the present study, we found that plasma HCSA was significantly elevated in half of the ALS patient cohort. It is worth noting that the increase in plasma HCSA was not associated with parallel increases in HCA. Since HCSA and HCA are both oxidised products of homocysteine one would expect that levels of these two molecules are likely to change in tandem, especially in pathological states. It is difficult at present to speculate upon the reason for the increased HCSA but not of HCA in ALS. It may be that the increased HCSA arise by increased oxidation of homocysteine, which is known to be elevated in patients with ALS [16]; it may be that the activity of oxidases that subsequently converts HCSA to HCA are decreased in ALS. In studies whereby brain extracts were incubated with [35S]-homocysteine and its derivatives examined by pre-column o-phthalaldehyde derivatization followed by HPLC, only a slow nonenzymic increase in HCSA was detected whereas the level of HCA was below the limit of sensitivity [15]. Such findings suggests that the biosynthesis of HCSA and HCA from homocysteine are somewhat varied. Recent metabolomics studies also show that the two molecules do not always change in tandem in some pathological states. One study performed high-resolution metabolomics to identify changes in serum metabolites in acute myocardial infarction and found that only HCSA (and CA) levels were increased and not of HCA [17]. Another metabolomics study found increased levels of HCSA only (and not of the other SAAs) in serum samples of stroke risk patients, as compared with control subjects [18]. Our finding of HCSA as the only SAA elevated in patient plasma further suggests that at least one of the three routes for elimination of homocysteine may be perturbed. As shown in Figure 1, there are three routes for elimination - homocysteine can either be recycled back to methionine or converted to cystathionine for production of cysteine, which is subsequently oxidised to CA and CSA (cystathionine pathway); alternatively, homocysteine can undergoes oxidation to produce HCSA and HCA (homocysteine oxidation pathway). Our findings suggest that the homocysteine oxidation pathway is induced in ALS, resulting in more excitatory amino acids, HCSA being generated.

Much immunocytochemical studies suggests that SAAs, including CA, CSA, HCA and HCSA are largely synthesised and released from CNS tissues [8]. Another possible source of HCSA is microbial metabolism of cysteine, which result in the production of SAAs. Eubacteria express bona fide enzymes such as Cysteine Dioxygenase (CDO) that can oxidize cysteine to CSA; phylogenetic analysis also indicate that CDO is distributed among several phyla that comprise the majority of the intestinal microbiota, including Actinobacteria, Firmicutes and Proteobacteria [12]. Collectively, these findings suggest that a large subset of the gut microbiota could contribute to the production of CSA and possibly other SAAs. The SAAs synthesised by intestinal microbes can enter the blood via effective transport systems in the intestinal tract. In fact, CA, CSA, HCA, HCSA are all substrates for the EAAT family of glutamate transporters [8] and EAAT3/EAAC1 is known to be expressed in the intestine [19]. However, we acknowledge that one limitation of our study is that we did not measure SSAs in the cerebrospinal fluid.
One limitation of this study is that we used LC-MRM-MS for CA, CSA, and HCSA, and ELISA for HCA. However, we compared the levels of the different SAAs between patients and controls, who were measured with the same methods. We did not attempt to compare the levels of the different SAAs.

The finding of elevated HCSA levels could have implications for ALS pathogenesis since HCSA is cytotoxic when tested on cerebral cortical neurons in vitro [20]. Studies have shown that SAAs are all effective agonists at several metabotropic glutamate receptors (mGluR). HCSA, HCA, CSA and CA are all reported to be more potent mGluR agonists than glutamate [21]. Of the four SAAs, HCSA is the most potent agonist at mGluR1, mGluR2, mGluR4, mGluR5, mGluR6 and mGluR8 [22]. Electrophysiological studies in hippocampal neurons also demonstrate HCSA can evoke activation of NMDA receptors [23]. Hyperactivation of glutamate receptors by SAAs can cause neuronal death through excitotoxicity. Examples include SAA-induced epileptic activity following direct administration to rodents [24] and SAA-induced toxicity in neuronal cell lines and spinal cord neurons [25]. Predictably, blockade of glutamate receptors was shown to prevent SAA-induced excitotoxicity [19, 26]. Thus, it is conceivable that the elevated HCSA that we have observed could act at both NMDA and non-NMDA glutamate receptors and cause excitotoxicity in some patients with ALS.
**FIGURE LEGENDS**

Fig 1. Structure of glutamate, aspartate and their sulphurs-containing analogues. The carboxyl group of glutamate or aspartate is replaced by a sulphinic group for homocysteic acid (HCA) and homocysteinesulfinic acid (HCSA), or a sulphonic group for cysteic acid (CA) and cysteine sulfinic acid (CSA).

Fig 2. Pathways of methionine metabolism and synthesis of sulphur amino acids. Black solid arrows indicate known reaction steps and dashed arrows indicate proposed steps. Numbers refer to enzymes involved in the reaction steps: 1, methionine adenosyl transferase; 2, S-Adenosylmethionine methyltransferase; 3, S-Adenosylhomocysteinase; 4, cystathionine β-synthase; 5, cystathionine γ-lyase; 6, cysteine dioxygenase; 7, cysteine sulfinate decarboxylase; 8, hypotaurine oxidase; 9, betaine homocysteine methyltransferase and methionine synthase. Diagram adapted from Thompson and Kilpatrick (1996)[4] and Do et al (1988)[9].

*Figure 3.* Individual value plots with mean (*horizontal line*) to show concentrations of cysteic acid (A), homocysteic acid (B), cysteinsulfinic acid (C) and homocysteinesulfinic acid (D) in plasma from ALS patients (38) and controls (30); ****p < 0.0001.

*Figure 4.* Comparison of homocysteinesulfinic acid levels in plasma from patients with Bulbar and Spinal onset; *p < 0.05.

**LEGEND FOR TABLE**

*Table 1:* Details of clinical features of participants

**STATEMENTS**

**Acknowledgement:** We acknowledge the support of the subjects who contributed to this study, and to our research nurses Susan Heggie and Kathryn Ann Thorpe.

**Ethics statement:** This study was approved by the Human Research Ethics Committee of the Royal Brisbane and Women’s Hospital (2006/047). All patients gave written informed consent to participation.

**Funding:** This study was supported by a Wesley Medical Research Grant awarded to PA McCombe and RD Henderson and by a grant from MND Research Australia to PA McCombe. There were no award numbers.

**Data availability:** Data is available from the authors on reasonable request

**Conflict of interest:** The authors have nothing to declare

**Author contributions:**
Dr Aven Lee conceived the study, carried out the experiments and wrote the first draft of the paper. Mr Buddhika Jayakody Arachchige carried out the experiments and contributed to writing the paper.
Dr Robert Henderson helped to recruit patients, and contributed to writing the paper.
Dr Jim Aylward helped to conceive the study and contributed to writing the paper.
Prof Pamela McCombe conceived the study, helped to recruit patients and contributed to writing the paper.
REFERENCES


glutamate

aspartate

HCA

CA

HCSA

CSA
Dietary Intake

Methionine →  S-Adenosylmethionine (SAM)

S-Adenosylhomocysteine (SAH)

Homocysteine

Cystathionine

Cysteine

Taurine →  Hypotaurine

CA ←  CSA ←  Cysteine

HCA ←  HCSA ←  Homocysteine

1  2  3  4  5  6  7  7  8
<table>
<thead>
<tr>
<th>Table 1. Clinical details of participants in the plasma SAA study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Healthy Controls</strong></td>
</tr>
<tr>
<td>Number of participants</td>
</tr>
<tr>
<td>Male: Female</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
</tr>
<tr>
<td>ALSFRS-R (mean ± SD)</td>
</tr>
<tr>
<td>Disease duration from onset (median, range) (days)</td>
</tr>
<tr>
<td>Site of onset (bulbar/upper limb/lower limb)</td>
</tr>
<tr>
<td>Number of patients with known family history of ALS</td>
</tr>
<tr>
<td>Number of patients with cognitive impairment</td>
</tr>
</tbody>
</table>